Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: The ENESTnd study

Francis J. Giles; Gianantonio Rosti; Photis Beris; Richard E. Clark; Philipp Le Coutre; Francois Xavier Mahon; Juan Luis Steegmann; Peter Valent; Giuseppe Saglio

doi:10.1586/ehm.10.61

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: The ENESTnd study

Francis J. Giles, Gianantonio Rosti, Photis Beris, Richard E. Clark, Philipp Le Coutre, Francois Xavier Mahon, Juan Luis Steegmann, Peter Valent, Giuseppe Saglio

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Review article › peer-review

34 Scopus citations

Abstract

Nilotinib (Tasigna®) is a more potent BCR-ABL inhibitor than imatinib and was designed to overcome imatinibs deficiencies. Nilotinib has significant efficacy in patients with chronic myeloid leukemia (CML) in chronic phase, accelerated phase and blastic phase, following imatinib failure. Based on the results of the Evaluating Nilotinib Efficacy and Safety in Clinical Trials - Newly Diagnosed Patients (ENESTnd) study, the US FDA has granted accelerated approval of nilotinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase. Imatinib has changed our perceptions of the therapeutic power of targeted inhibition of a pathologically active kinase. Nilotinib, a designer agent built on the imatinib scaffold, has proven superior to its template agent by every significant surrogate marker we use in monitoring CML. Nilotinibs clinical superiority over imatinib, as demonstrated by the ENESTnd study, has established it as an agent that we believe is a significant further step towards the cure of CML.

Original language	English (US)
Pages (from-to)	665-673
Number of pages	9
Journal	Expert Review of Hematology
Volume	3
Issue number	6
DOIs	https://doi.org/10.1586/ehm.10.61
State	Published - Dec 2010

Keywords

ABL kinase inhibitors
ENESTnd
FDA approval
chronic myeloid leukemia
first-line therapy
imatinib
nilotinib

ASJC Scopus subject areas

Hematology

Access to Document

10.1586/ehm.10.61

Cite this

@article{5e004f8fef9943c5ba1e0801b3c82b7f,

title = "Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: The ENESTnd study",

abstract = "Nilotinib (Tasigna{\textregistered}) is a more potent BCR-ABL inhibitor than imatinib and was designed to overcome imatinibs deficiencies. Nilotinib has significant efficacy in patients with chronic myeloid leukemia (CML) in chronic phase, accelerated phase and blastic phase, following imatinib failure. Based on the results of the Evaluating Nilotinib Efficacy and Safety in Clinical Trials - Newly Diagnosed Patients (ENESTnd) study, the US FDA has granted accelerated approval of nilotinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase. Imatinib has changed our perceptions of the therapeutic power of targeted inhibition of a pathologically active kinase. Nilotinib, a designer agent built on the imatinib scaffold, has proven superior to its template agent by every significant surrogate marker we use in monitoring CML. Nilotinibs clinical superiority over imatinib, as demonstrated by the ENESTnd study, has established it as an agent that we believe is a significant further step towards the cure of CML.",

keywords = "ABL kinase inhibitors, ENESTnd, FDA approval, chronic myeloid leukemia, first-line therapy, imatinib, nilotinib",

author = "Giles, {Francis J.} and Gianantonio Rosti and Photis Beris and Clark, {Richard E.} and {Le Coutre}, Philipp and Mahon, {Francois Xavier} and Steegmann, {Juan Luis} and Peter Valent and Giuseppe Saglio",

year = "2010",

month = dec,

doi = "10.1586/ehm.10.61",

language = "English (US)",

volume = "3",

pages = "665--673",

journal = "Expert Review of Hematology",

issn = "1747-4086",

publisher = "Taylor and Francis Ltd.",

number = "6",

}

TY - JOUR

T1 - Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia

T2 - The ENESTnd study

AU - Giles, Francis J.

AU - Rosti, Gianantonio

AU - Beris, Photis

AU - Clark, Richard E.

AU - Le Coutre, Philipp

AU - Mahon, Francois Xavier

AU - Steegmann, Juan Luis

AU - Valent, Peter

AU - Saglio, Giuseppe

PY - 2010/12

Y1 - 2010/12

N2 - Nilotinib (Tasigna®) is a more potent BCR-ABL inhibitor than imatinib and was designed to overcome imatinibs deficiencies. Nilotinib has significant efficacy in patients with chronic myeloid leukemia (CML) in chronic phase, accelerated phase and blastic phase, following imatinib failure. Based on the results of the Evaluating Nilotinib Efficacy and Safety in Clinical Trials - Newly Diagnosed Patients (ENESTnd) study, the US FDA has granted accelerated approval of nilotinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase. Imatinib has changed our perceptions of the therapeutic power of targeted inhibition of a pathologically active kinase. Nilotinib, a designer agent built on the imatinib scaffold, has proven superior to its template agent by every significant surrogate marker we use in monitoring CML. Nilotinibs clinical superiority over imatinib, as demonstrated by the ENESTnd study, has established it as an agent that we believe is a significant further step towards the cure of CML.

AB - Nilotinib (Tasigna®) is a more potent BCR-ABL inhibitor than imatinib and was designed to overcome imatinibs deficiencies. Nilotinib has significant efficacy in patients with chronic myeloid leukemia (CML) in chronic phase, accelerated phase and blastic phase, following imatinib failure. Based on the results of the Evaluating Nilotinib Efficacy and Safety in Clinical Trials - Newly Diagnosed Patients (ENESTnd) study, the US FDA has granted accelerated approval of nilotinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase. Imatinib has changed our perceptions of the therapeutic power of targeted inhibition of a pathologically active kinase. Nilotinib, a designer agent built on the imatinib scaffold, has proven superior to its template agent by every significant surrogate marker we use in monitoring CML. Nilotinibs clinical superiority over imatinib, as demonstrated by the ENESTnd study, has established it as an agent that we believe is a significant further step towards the cure of CML.

KW - ABL kinase inhibitors

KW - ENESTnd

KW - FDA approval

KW - chronic myeloid leukemia

KW - first-line therapy

KW - imatinib

KW - nilotinib

UR - http://www.scopus.com/inward/record.url?scp=78649501550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649501550&partnerID=8YFLogxK

U2 - 10.1586/ehm.10.61

DO - 10.1586/ehm.10.61

M3 - Review article

C2 - 21091142

AN - SCOPUS:78649501550

SN - 1747-4086

VL - 3

SP - 665

EP - 673

JO - Expert Review of Hematology

JF - Expert Review of Hematology

IS - 6

ER -

Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: The ENESTnd study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this